{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T04:25:40Z","timestamp":1789014340034,"version":"build-2803163510"},"reference-count":37,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,5,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Lenalidomide is an immunomodulatory drug approved for maintenance treatment in newly diagnosed multiple myeloma, and it has been shown to improve progression-free survival (PFS) and, in several studies, overall survival. Nevertheless, the impact of prolonged treatment with lenalidomide on the kinetics of minimal residual disease (MRD) and its prognostic impact have not been studied in depth. To obtain better knowledge in this regard, we retrospectively analyzed 139 patients who received lenalidomide maintenance in real-world clinical practice and whose MRD levels were observed during the treatment period by multiparametric flow cytometry or next-generation sequencing with a sensitivity of at least 10\u22124. Lenalidomide maintenance correlated with an increased depth of the disease response, with 38.1% of patients achieving maximal response during maintenance. Moreover, 34.3% of patients who were MRD positive after induction treatment achieved MRD-negative status during maintenance and ultimately had improved PFS. Sequential MRD assessments identified patients with progressively decreasing MRD levels who also had better PFS outcomes, compared with patients not showing a decreasing pattern of MRD. These results support the role of maintenance therapy, not only to sustain, but also to increase the depth of disease response with a PFS benefit. In addition, MRD monitoring during maintenance identifies patients with better prognosis and may help in their clinical management.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001508","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T18:30:15Z","timestamp":1589999415000},"page":"2163-2171","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":33,"title":["Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3774-118X","authenticated-orcid":false,"given":"Rafael","family":"Alonso","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain;"},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5851-3720","authenticated-orcid":false,"given":"Mar\u00eda-Teresa","family":"Cedena","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain;"},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Wong","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Shah","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8193-1402","authenticated-orcid":false,"given":"Rafael","family":"R\u00edos-Tamayo","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Univeristario Virgen de las Nieves (HVN), Consorcio de Investigaci\u00f3n Biom\u00e9dica en Red de Epidemiolog\u00eda y Salud P\u00fablica (CIBERESP), Granada, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9080-1466","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Moraleda","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Cl\u00ednico Universitario Virgen de la Arrixaca, Insitituto Muriano Investigaci\u00f3n Biosanitaria (IMIB)\u2013Arrixaca, Universidad de Murcia, Murcia, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"L\u00f3pez-Jim\u00e9nez","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Garc\u00eda","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain;"},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Bahri","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Valeri","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain;"},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6383-0381","authenticated-orcid":false,"given":"Ricardo","family":"S\u00e1nchez","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain;"},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Collado-Yurrita","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Martin","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Wolf","sequence":"first","affiliation":[{"name":"Division of Hematology\/Oncology, Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3393-9570","authenticated-orcid":false,"given":"Juan-Jos\u00e9","family":"Lahuerta","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain;"},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Mart\u00ednez-L\u00f3pez","sequence":"first","affiliation":[{"name":"Department of Hematology, Hospital Universitario 12 de Octubre (H12O), Universidad Complutense de Madrid, Madrid, Spain;"},{"name":"Clinical Research Hematology Unit, H12O Centro Nacional de Investigaciones Oncol\u00f3gicas (CNIO), Centro de Investigaci\u00f3n Biom\u00e9dica en Red C\u00e1ncer (CIBERONC), Madrid, Spain;"},{"name":"Division of Hematology\/Oncology, Hellen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"issue":"7","key":"2020052011343268000_B1","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s00432-018-2641-5","article-title":"Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis","volume":"144","author":"Cerrato","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2020052011343268000_B2","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/leu.2017.256","article-title":"Outcomes of maintenance therapy with lenalidomide or bortezomib in multiple myeloma in the setting of early autologous stem cell transplantation","volume":"32","author":"Chakraborty","year":"2018","journal-title":"Leukemia"},{"issue":"10","key":"2020052011343268000_B3","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jamaoncol.2018.2961","article-title":"Maintenance Treatment and Survival in Patients With Myeloma: A Systematic Review and Network Meta-analysis","volume":"4","author":"Gay","year":"2018","journal-title":"JAMA Oncol"},{"issue":"2","key":"2020052011343268000_B4","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.bbmt.2016.11.010","article-title":"Outcomes of Maintenance Therapy with Bortezomib after Autologous Stem Cell Transplantation for Patients with Multiple Myeloma","volume":"23","author":"Sivaraj","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"2020052011343268000_B5","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"19","key":"2020052011343268000_B6","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2020052011343268000_B7","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"2020052011343268000_B8","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"12","key":"2020052011343268000_B9","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1007\/s00277-018-3446-y","article-title":"Impact of post-transplantation maintenance therapy on health-related quality of life in patients with multiple myeloma: data from the Connect\u00ae MM Registry","volume":"97","author":"Abonour","year":"2018","journal-title":"Ann Hematol"},{"issue":"7","key":"2020052011343268000_B10","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.clinthera.2018.05.017","article-title":"Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry","volume":"40","author":"Rifkin","year":"2018","journal-title":"Clin Ther"},{"issue":"13","key":"2020052011343268000_B11","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/bloodadvances.2018017186","article-title":"Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM [published correction appears in Blood Adv. 2020;4(3):444]","volume":"2","author":"Jagannath","year":"2018","journal-title":"Blood Adv"},{"issue":"7","key":"2020052011343268000_B12","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3324\/haematol.2018.202200","article-title":"Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients","volume":"104","author":"Jones","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"2020052011343268000_B13","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cncr.31854","article-title":"Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: a pooled analysis","volume":"125","author":"Gambella","year":"2019","journal-title":"Cancer"},{"issue":"24","key":"2020052011343268000_B14","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020052011343268000_B15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"issue":"8","key":"2020052011343268000_B16","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ajh.25507","article-title":"Imaging and bone marrow assessments improve minimal residual disease prediction in multiple myeloma","volume":"94","author":"Alonso","year":"2019","journal-title":"Am J Hematol"},{"issue":"12","key":"2020052011343268000_B17","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1200\/JCO.2010.33.1967","article-title":"Comparison of immunofixation, serum free light chain, and immunophenotyping for response evaluation and prognostication in multiple myeloma","volume":"29","author":"Paiva","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"2020052011343268000_B18","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"issue":"8","key":"2020052011343268000_B19","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"key":"2020052011343268000_B20","unstructured":"Division of Cancer Treatment and Diagnosis, National Cancer Institute: Common Terminology Criteria for Adverse Events (CTCAE); Protocol Development; Adverse Events\/CTEP. Bethesda, MD: National Institutes of Health, National Cancer Institute; 2019. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 29 September 2019."},{"issue":"29","key":"2020052011343268000_B21","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","article-title":"Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis","volume":"35","author":"McCarthy","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020052011343268000_B22","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2020052011343268000_B23","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.18632\/oncotarget.12641","article-title":"Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis","volume":"8","author":"Oliva","year":"2017","journal-title":"Oncotarget"},{"issue":"23","key":"2020052011343268000_B24","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"issue":"3","key":"2020052011343268000_B25","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bbmt.2018.12.687","article-title":"Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study","volume":"25","author":"Hahn","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"16","key":"2020052011343268000_B26","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplantation in multiple myeloma","volume":"134","author":"Rosi\u00f1ol","year":"2019","journal-title":"Blood"},{"issue":"2","key":"2020052011343268000_B27","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/10428194.2018.1473577","article-title":"Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma","volume":"60","author":"Amsler","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"2020052011343268000_B28","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/cncr.30366","article-title":"Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"122","author":"Mian","year":"2016","journal-title":"Cancer"},{"issue":"6","key":"2020052011343268000_B29","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma","volume":"31","author":"Martinez-Lopez","year":"2017","journal-title":"Leukemia"},{"issue":"23","key":"2020052011343268000_B30","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM\/DFCI 2009 Trial [abstract]","volume":"126","author":"Avet-Loiseau","year":"2015","journal-title":"Blood"},{"issue":"10","key":"2020052011343268000_B31","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.clml.2019.09.005","article-title":"Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA","volume":"19","author":"Avet-Loiseau","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2020052011343268000_B32","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"issue":"25","key":"2020052011343268000_B33","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"2020052011343268000_B34","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"2020052011343268000_B35","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"issue":"19","key":"2020052011343268000_B36","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"12","key":"2020052011343268000_B37","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1038\/bcj.2016.114","article-title":"Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial","volume":"6","author":"Jones","year":"2016","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/10\/2163\/1731615\/advancesadv2020001508.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/10\/2163\/1731615\/advancesadv2020001508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T18:30:42Z","timestamp":1589999442000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/10\/2163\/456020\/Prolonged-lenalidomide-maintenance-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,5,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001508","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}